Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weight Loss Products Aim To Be "Heavy" Hitters After NNFA Debut

This article was originally published in The Tan Sheet

Executive Summary

Diet systems and weight loss products - many containing the ever-controversial stimulant ingredient ephedra - remain a popular category in the supplement market. Twinlab and Natrol were among several firms introducing new weight loss items at the National Nutritional Foods Association MarketPlace 2000 trade show in Las Vegas July, 26-29.

You may also be interested in...



Ephedrine Supplement Risks, Outcome Variables Subject Of USPHS Meeting

A government public health expert panel will hear comments on whether ephedrine alkaloid-containing dietary supplements labeled for weight loss and exercise pose risks to consumers at an Aug. 8-9 meeting in Washington, D.C. The meeting is being sponsored by the Office of Women's Health.

Ephedrine Alkaloid Weight-Loss Claims Proposed Ban Lifted By FDA

FDA is withdrawing a proposed prohibition on claims that promote long-term use of ephedrine alkaloid-containing dietary supplements, such as claims for weight loss and bodybuilding.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel